Breaking News Instant updates and real-time market news.

NFLX

Netflix

$190.12

0.56 (0.30%)

, DIS

Disney

$111.27

0.7 (0.63%)

20:03
12/17/17
12/17
20:03
12/17/17
20:03

On The Fly: Top five weekend stock stories

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Humana (HUM) is in advanced talks to buy Kindred Healthcare (KND) in partnership with private firms Welsh, Carson, Anderson & Stowe and TPG, according to Reuters. 2. Oracle (ORCL) announced that it has entered into an agreement with Aconex, a leading cloud-based solution that manages team collaboration for construction projects. The transaction is valued at approximately $1.2B, net of Aconex cash. 3. Netflix (NFLX) success and its high valuation is forcing the rest of the TV work to scramble, Alex Eule wrote in this week's edition of Barron's. In the wake of Disney's (DIS) 21st Century Fox (FOXA; FOX) purchase, investors should expect more consolidation to come, he added. Given that FOX RSN business looks very similar to MSG Networks (MSGN) and with Disney's deal spurring a new wave of RSN interest, 208 could be the year that MSG gets sold, Barron's says. Other potential attractive targets include AMC (AMCX) and Viacom (VIAB), Eule contended. 4. Disney and Lucasfilm's "Star Wars: The Last Jedi" opened to a near-record $220M in North America, the second-best showing behind "Star Wars: The Force Awakens." Internationally, the movie took in $230M from 54 markets. "The Last Jedi" received an A CinemaScore and got a 93% from Rotten Tomatoes. 5. Spark Therapeutics (ONCE), Alaska Air (ALK) saw positive mentions in Barron's, while Exxon (XOM) was mentioned cautiously.

NFLX

Netflix

$190.12

0.56 (0.30%)

DIS

Disney

$111.27

0.7 (0.63%)

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

FOX

21st Century Fox

MSGN

MSG Networks

$19.80

0.05 (0.25%)

AMCX

AMC Networks

$55.33

1.16 (2.14%)

VIAB

Viacom

$30.24

0.53 (1.78%)

VIA

Viacom

$34.40

0.25 (0.73%)

XOM

Exxon Mobil

$83.03

0.13 (0.16%)

ONCE

Spark Therapeutics

$46.37

1.16 (2.57%)

ALK

Alaska Air

$70.83

1.44 (2.08%)

ORCL

Oracle

$48.30

-1.89 (-3.77%)

HUM

Humana

$253.64

3.03 (1.21%)

KND

Kindred Healthcare

$8.60

0.45 (5.52%)

  • 12

    Jan

  • 08

    Feb

  • 08

    Feb

NFLX Netflix
$190.12

0.56 (0.30%)

12/06/17
PIPR
12/06/17
NO CHANGE
Target $240
PIPR
Overweight
Piper sees high likelihood of Q4 subscriber upside for Netflix
Piper Jaffray analyst Michael Olson says his analysis of Netflix search trends suggests upside potential for both international and domestic subscriber in Q4. The analyst models 9.3% year-over-year domestic sub growth in Q4 while his search index points to 14.8% growth. For international, Olson models 38.7% year-over-year sub growth while his index points to 54.5% growth. The index is directionally positive and shows a high likelihood of Q4 subscriber upside for Netflix, Olson tells investors in a research note. He maintains an Overweight rating on the shares with a $240 price target.
12/06/17
12/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alibaba (BABA) initiated with a Positive at Susquehanna. 2. WWE (WWE) initiated with an Overweight at JPMorgan. 3. Facebook (FB), Alphabet Class A (GOOGL), and Amazon.com (AMZN) were initiated with an Outperform at Evercore ISI, while Netflix (NFLX) was initiated with an In Line. 4. Applied Materials (AMAT) initiated with an Outperform at Wells Fargo. 5. Delphi Technologies (DLPH) was initiated with an Overweight at Barclays while being initiated with a Neutral at BofA/Merrill and UBS. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/13/17
BTIG
12/13/17
NO CHANGE
BTIG
Disney, Fox deal may be a near-term positive for Netflix, BTIG says
Commenting on Disney's (DIS) deal with Fox (FOX; FOXA) and its potential implications, BTIG's Richard Greenfield notes that the knee jerk reaction he hears across the investment world is the former is buying the later to build their "Netflix killer." Greenfield "strongly disagrees" with this viewpoint, saying that if Disney wanted to build a Netflix competitor it should be eliminating its stock buyback and aggressively investing in content that has no legacy media strings attached. Further, the Disney/Fox transaction is likely a near-to-intermediate term positive for Netflix, he argues, adding that both companies will be tied up in a 12 month or more regulatory review process with thousands of executives in limbo pending the closing of the transaction.
12/15/17
LOOP
12/15/17
NO CHANGE
Target $106
LOOP
Hold
Disney's Star Wars opening weekend estimated remains $225M, says Loop Capital
Loop Capital analyst David Miller keeps his Hold rating and $106 price target on Disney (DIS), forecasting the opening weekend box office for Star Wars: The Last Jedi at $225M, the ultimate domestic take of $850M, and global revenue of $1.7B. The analyst says the film was "awesome" - as good, if not better than The Force Awakens which cleared $2.07B in global box office. Miller also notes that Disney discussed the implications of the company taking managerial control over Hulu, saying CEO Bob Iger appeared non-committal on whether to use Hulu as the head-to-head competitor with Netflix (NFLX) or await its Direct-To-Consumer product to be launched in mid-2019.
DIS Disney
$111.27

0.7 (0.63%)

12/15/17
WELS
12/15/17
NO CHANGE
Target $135
WELS
Outperform
Disney price target raised to $135 from $116 at Wells Fargo
Wells Fargo analyst Marci Ryvicker raised her price target for Disney (DIS) shares to $135 following the company's acquisition of 21st Century Fox (FOXA) assets. The analyst is positive on the deal and sees "significant potential upside" for Disney. She notes, however, that the new company is more complex given the consolidation of Hulu and addition of Sky. Ryvicker keeps Outperform rating on Disney shares.
12/15/17
KEYB
12/15/17
DOWNGRADE
KEYB
Sector Weight
21st Century Fox downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Andy Hargreaves downgraded 21st Century Fox (FOXA) to Sector Weight saying that while he views the asset sale to Disney (DIS) as positive for both sides, regulatory risks are high. The analyst sees total potential value in the deal at $42 for Fox shares, but feels a discount is warranted given the regulatory risk. Hargreaves believes current fair value for Fox shares is $37.
12/15/17
EDJN
12/15/17
DOWNGRADE
EDJN
Hold
Disney downgraded to Hold from Buy at Edward Jones
Edward Jones analyst downgraded Disney (DIS) to Hold from Buy saying the acquisition of 21st Century Fox (FOXA) increase Disney's dependency on cable networks and adds various complexities. Additionally, the firm's analyst views Disney shares as fairly valued following recent share appreciation in light of the deal.
FOXA 21st Century Fox
$34.99

0.11 (0.32%)

12/15/17
PIPR
12/15/17
NO CHANGE
Target $125
PIPR
Overweight
Piper raises price targets for both Disney and 21st Century Fox
Piper Jaffray analyst Stan Meyers raised his price target for Disney (DIS) shares to $125 from $120 and his target for 21st Century Fox (FOXA) shares to $40 from $35 following the yesterday's asset sale deal. The analyst has Overweight ratings on both names. He believes the transaction is mutually beneficial. Disney unlocks intellectual property value "better than anyone," and can extract better economics with counterparties via scale, while Fox's leaner structure allows it to rerate higher, execute on core competencies, and generate "significant" free cash flow for shareholders, Meyers tells investors in a research note.
FOX 21st Century Fox

12/13/17
FBNS
12/13/17
NO CHANGE
FBNS
FBN says Fox could be worth over $42 per share with Disney deal
With multiple media report indicating that Disney (DIS) is close to finalizing a deal to buy most of 21st Century Fox's (FOX) assets and operations, FBN Securities analyst Robert Routh is estimating that Fox shares could have a "real value" of $42.46 based on what has been reported on the likely deal. This estimate is before considering taxes and taking into account that Disney shares will likely rise after a deal is confirmed, said Routh, who does not officially cover either Disney or Fox.
12/11/17
BTIG
12/11/17
NO CHANGE
BTIG
BTIG says Comcast could pay 'significantly' more for Fox assets than Disney
BTIG analyst Richard Greenfield said earlier in a note to investors that he believes Comcast (CMCSA) could pay "significantly more" for the assets that Fox (FOXA) is reportedly looking to sell than could Disney (DIS). He also believes Comcast could have a better chance of securing regulatory approval for a deal if they are willing to spin off all of the regional sports networks that a combined entity would own.
11/10/17
BERN
11/10/17
NO CHANGE
Target $101
BERN
Market Perform
Disney deal for Fox wouldn't solve underlying problems, says Bernstein
Bernstein analyst Todd Juenger noted that Disney (DIS) has gone from a situation where reported EPS was going up but its stock price was going down to one where EPS is going down but the stock has been going up a bit driven by M&A speculation. However, he contends that the current round of renewed M&A speculation is happening because underlying fundamentals are "so bad" and even if a deal for Disney to buy Fox (FOXA) assets happens it wouldn't solve the underlying problems. He also thinks the chances of a Disney-Fox deal as currently described are "very low." Juenger maintains a Market Perform rating and $101 price target on Disney shares.
MSGN MSG Networks
$19.80

0.05 (0.25%)

10/11/17
LOOP
10/11/17
UPGRADE
Target $25
LOOP
Buy
MSG Networks upgraded to Buy from Hold at Loop Capital
Loop Capital analyst David Miller upgraded MSG Networks to Buy and raised his price target for the shares to $25 from $19. The company's free cash flow generation, both in the upcoming quarter and for all of fiscal year 2018, "will finally supercharge" its net debt/AOI ratio down to below 3.0 times by the end of the fiscal year, Miller tells investors in a research note. He believes the market is "underestimating the pace at which that will happen."
10/31/17
MSCO
10/31/17
DOWNGRADE
Target $20
MSCO
Underweight
MSG Networks downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne downgraded MSG Networks to Underweight from Equal Weight, stating that breaking up cable bundles may weigh on sports networks and he believes consensus expectations for EBITDA growth in FY19 and beyond look optimistic. The analyst, who assumes MSG Networks' long-term EBITDA declines, lowered his estimates and cut his price target on the stock to $20 from $24.
08/30/17
FBNS
08/30/17
UPGRADE
Target $26.92
FBNS
Outperform
MSG Networks upgraded to Outperform from Sector Perform at FBN Securities
FBN Securities analyst Robert Rougth upgraded MSG Networks to Outperform with a price target of $26.92 saying shares now trade at 7.4x 2018 estimated AOI compared with his last note when equity was at 8.5x the same metric.
09/11/17
BTIG
09/11/17
NO CHANGE
Target $260
BTIG
Buy
Knicks sale would not be surprising after Rockets deal, says BTIG
BTIG analyst Brandon Ross noted that James Dolan and family have been actively unwinding their ties to the legacy TV bundle, both by splitting Madison Square Garden (MSG) from MSG Networks (MSGN) and via the sale of Cablevision to Altice (ATCEY). He also notes that Dolan is on record that he believes sports rights are in a bubble. Given all of this, and the recent big-ticket sale of the Houston Rockets, Ross would not be surprised to see Dolan consider a sale of the Knicks and/or Rangers, adding that selling one team or both could pave the way for an eventual "go-private" deal for the rest of MSG and its remaining live entertainment business. Ross keeps a Buy rating and $260 price target on Madison Square Garden shares.
AMCX AMC Networks
$55.33

1.16 (2.14%)

10/12/17
10/12/17
DOWNGRADE
Target $105

Neutral
Disney downgraded to Neutral on increased pay-TV caution at Guggenheim
As previously reported, Guggenheim analyst Michael Morris downgraded Disney (DIS) to Neutral from Buy, citing his increased caution toward pay-TV trends and concern that expectations for the contribution from its content cycle are too high. While he is optimistic about the company's proposed direct-to-consumer streaming products, he expects the initial investment and long lead time into the launch to weigh on sentiment over the next 12 months, Morris tells investors. The analyst, who lowered his price target on Disney to $105 from $122, also downgraded Viacom (VIAB) and AMC Networks (AMCX) this morning.
10/12/17
GUGG
10/12/17
DOWNGRADE
GUGG
Neutral
AMC Networks downgraded to Neutral from Buy at Guggenheim
10/12/17
10/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wal-Mart (WMT) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Matthew Fassler saying shares have achieved in three months what he had expected in a year on an improvement in sentiment, but not on higher earnings estimates. 2. Monro (MNRO) downgraded to Hold from Buy at Jefferies with analyst Bret Jordan citing expectations the company's earnings growth will slow in 2018 as its focus shifts from acquisitions to improving store-level execution. 3. Diamond Offshore (DO) downgraded to Sell from Neutral at Citi with analyst Scott Gruber saying that if an upturn is forthcoming, Transocean should outperform given a "diminution" of concern toward its balance sheet and more new contract catalysts. 4. Cummins (CMI) downgraded to Neutral following dealer checks at Longbow with analyst Faheem Sabeiha citing a recent truck dealer survey that suggests initial 2018 sales growth is below current industry forecasts, partly due to driver shortage concerns. 5. Disney (DIS), AMC Networks (AMCX), and Viacom (VIA, VIAB) were downgraded to Neutral from Buy at Guggenheim. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/12/17
10/12/17
DOWNGRADE
Target $60

Neutral
AMC Networks downgraded to Neutral on ad growth concerns at Guggenheim
As previously reported, Guggenheim analyst Michael Morris downgraded AMC Networks to Neutral from Buy, citing his concern about advertising growth trends and increased pressure from digital video competitors. He now forecasts 2018 domestic advertising revenue will decline by 2.3%, with a 6.2% decline at flagship AMC, as The Walking Dead continues to mature and potentially lose audience, he tells investors. Morris lowered his price target on AMC Networks to $60 from $73.
VIAB Viacom
$30.24

0.53 (1.78%)

11/17/17
RBCM
11/17/17
NO CHANGE
Target $23
RBCM
Underperform
Viacom price target lowered to $23 from $30 at RBC Capital
RBC Capital analyst Steven Cahall lowered his price target on Viacom to $23 following Q4 results. Cahall says that despite the EPS beat, weaker domestic affiliate revenue growth was the latest surprising development as part of a trend of negative estimate revisions. The analyst keeps his Underperform rating, saying that investors are cautious on exposure to Media amid a "gravitational pull toward more visible growth stories", particularly as Viacom undergoes a period of strategic restructuring.
11/29/17
KEYB
11/29/17
NO CHANGE
KEYB
Q3 results, analysis of Q4 viewership trends show some bright spots, says KeyBanc
KeyBanc analyst Andy Hargreaves notes that the Department of Justice's decision to sue to block AT&T (T)/Time Warner (TWX) seems likely to halt additional M&A until a resolution is reached. Additionally, the analyst points out that Q4 viewership trends appear most positive for Discovery (DISCA), Viacom (VIAB) so far, and 21st Century Fox (FOXA) remains his favorite long among TV network stocks.
11/20/17
11/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Verizon (VZ) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jennifer Fritzsche saying after dropping 16% since mid-January, "much of the bad news is behind the stock" in terms of wireless service revenue declines. 2. 3D Systems (DDD) upgraded to Neutral from Underweight at Piper Jaffray with analyst Troy Jensen saying he sees limited downside from current share levels. 3. Viacom (VIAB, VIA) upgraded to Hold from Sell at Deutsche Bank with analyst Bryan Kraft saying he sees limited room for further multiple compression. 4. Maxwell (MXWL) upgraded to Buy from Neutral at Roth Capital with analyst Craig Irwin saying he sees consensus estimates as achievable for 2018, and merger synergies with NessCap should start making a more material contribution over the next few quarters. 5. National Beverage (FIZZ) upgraded to Positive from Neutral at Susquehanna with analyst Pablo Zuanic citing his increased conviction on the sales and bottom-line upside of the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/20/17
DBAB
11/20/17
UPGRADE
Target $25
DBAB
Hold
Viacom upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Bryan Kraft upgraded Viacom to Hold saying he sees limited room for further multiple compression. The analyst believes reports of merger speculation in the media space should provide valuation support and he keeps a $25 price target for Viacom shares.
VIA Viacom
$34.40

0.25 (0.73%)

10/13/17
MSCO
10/13/17
NO CHANGE
Target $38
MSCO
Overweight
Viacom could be pushed back above $30 by Charter pact, says Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne noted press reports suggesting a negotiation going on between Viacom (VIAB) and Charter (CHTR) on a carriage agreement renewal and he is now modeling a nearly 15% one-time decline in blended affiliate fee pricing across Charter's footprint in exchange for broad distribution. If Viacom's networks get continued carriage on Charter, even with reduced fees, this could drive Viacom shares back above $30, contends Swinburne. He lowered his price target on Viacom to $38 from $42, but keeps an Overweight rating on the stock, noting that in any case the Charter relationship overhang will likely be removed by month end.
XOM Exxon Mobil
$83.03

0.13 (0.16%)

11/07/17
11/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Priceline (PCLN) downgraded to Neutral from Buy at Guggenheim. 2. Exxon Mobil (XOM) downgraded to Reduce from Hold at HSBC with analyst Gordon Gray saying he compares Exxon's valuation to Buy rated Shell's (RDS.A) saying it is a third higher, yet Shell generated $7B more underlying cash flow in the past 12 months, and he thinks Exxon's capex will rise by much more in 2018 in comparison. 3. Teva (TEVA) downgraded to Reduce from Hold at HSBC with analyst Steve McGarry saying the balance sheet is "over-stretched." 4. Cabot Oil & Gas (COG) downgraded to Hold from Buy at Drexel Hamilton with analyst Bob Christensen citing the temporary stay issued on the Atlantic Sunrise pipeline. 5. SMIC (SMI) downgraded to Underperform from Neutral at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/16/17
RBCM
11/16/17
NO CHANGE
Target $85
RBCM
Sector Perform
Exxon Mobil price target lowered to $85 from $90 at RBC Capital
RBC Capital analyst Biraj Borkhataria lowered the price target on Exxon Mobil to $85 and kept his Sector Perform rating. Borkhataria says that while the company's dividend yield is attractive historically, there is limited scope for the company to raise is share buybacks materially given that its surplus cash will likely be used to fund asset acquisitions.
12/11/17
FBCO
12/11/17
INITIATION
FBCO
Neutral
Exxon Mobil initiated with a Neutral at Credit Suisse
Credit Suisse analyst William Featherston initiated Exxon Mobil with a Neutral rating and $83 price target.
12/12/17
12/12/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mylan (MYL), Teva (TEVA) and Endo (ENDP) initiated with a Neutral at Gugenheim, while Impax (IPXL) was initiated with a Buy. 2. Stitch Fix (SFIX) initiated with an Outperform at William Blair, a Neutral at JPMorgan and Goldman Sachs, an Overweight at Piper Jaffray, an Equal Weight at Barclays and a Hold at Stifel. 3. Exxon Mobil (XOM) and ConocoPhillips (COP) initiated with a Neutral at Credit Suisse. The firm also started Range Resources (RRC) and Anadarko (APC) with an Outperform, and Laredo Petroleum (LPI), Energen (EGN), Southwestern Energy (SWN), Noble Energy (NBL), Murphy Oil (MUR), Cabot Oil & Gas (COG) and Newfield Exploration (NFX) with a Neutral rating. 4. Restaurant Brands (QSR) initiated with an Outperform at Evercore ISI. 5. Waste Connections (WCN) initiated with an Outperform, named a top pick at BMO Capital. This list is just a portion of The Fly's full analyst coverage. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ONCE Spark Therapeutics
$46.37

1.16 (2.57%)

12/14/17
GSCO
12/14/17
DOWNGRADE
Target $58
GSCO
Neutral
Goldman downgrades Spark Therapeutics on lack of 2018 catalysts
Goldman Sachs analyst Salveen Richter downgraded Spark Therapeutics to Neutral from Buy and cut his price target for the shares to $58 from $106. The analyst sees limited "value-driving" catalysts in 2018. Richter expects Luxturna to receive U.S. approval by January 12 with a "decent likelihood" of a successful launch, but estimates this program is already reflected in the valuation. Further, he believes SPK-8011 in hemophilia A lost its "spark" following the recent data readout. Richter this morning also upgraded GW Pharmaceuticals (GWPH) to Buy.
12/14/17
GSCO
12/14/17
DOWNGRADE
GSCO
Neutral
Spark Therapeutics downgraded to Neutral from Buy at Goldman Sachs
12/13/17
LEHM
12/13/17
NO CHANGE
Target $54
LEHM
Overweight
Spark Therapeutics selloff brings good entry point, says Barclays
Barclays analyst Gena Wang believes this week's selloff in shares of Spark Therapeutics has brought a good entry point. The risk/reward is favorable as hemophilia A seems largely removed from the valuation, Wang tells investors in a research note. She believes current data are limited and likely too early to suggest complete dismissal of the program. The analyst lowered her price target for Spark shares to $54 from $107 and removed the stock as her Top Pick. Wang, however, keeps an Overweight rating on the name.
12/13/17
BERN
12/13/17
NO CHANGE
Target $71
BERN
Outperform
Spark Therapeutics price target lowered to $71 from $90 at Bernstein
Bernstein analyst Vincent Chen lowered his price target for Spark Therapeutics to $71 from $90 after the disappointing hemophilia A data at ASH. The analyst reiterates an Outperform rating on the shares.
ALK Alaska Air
$70.83

1.44 (2.08%)

11/16/17
MSCO
11/16/17
NO CHANGE
Target $78
MSCO
Overweight
Alaska Air named top pick in U.S. airlines at Morgan Stanley
Morgan Stanley analyst Rajeev Lalwani moved Alaska Air (ALK) up to be his top pick in the U.S. airline space, saying he has become more bullish on the stock given bottoming trends, solid relative fundamentals, and its discounted valuation following the selloff after its Q3 earnings report. Lalwani maintains an Overweight rating and $78 price target on Alaska Air.
12/04/17
COWN
12/04/17
NO CHANGE
Target $89
COWN
Outperform
Alaska Air a top pick for 2018, says Cowen
Cowen analyst Helane Becker is calling Alaska Air a top pick for 2018. She said the current share price fully reflects the operational missteps and pricing pressure from substantial growth in 2017. She believes there are catalysts to drive the shares higher, including taking market share form other larger carriers. Becker reiterated her Outperform rating and $89 price target on Alaska Air shares.
12/14/17
RAJA
12/14/17
NO CHANGE
RAJA
Raymond James Analysts' Best Picks for 2018
Raymond James named its Analysts' Best Picks for 2018. They are: Alaska Air (ALK), Alibaba (BABA), Becton Dickinson (BDX), Broadcom (AVGO), Continental Resources (CLR), Dollar Tree (DLTR), Fastenal (FAST), First Horizon (FHN), Flir Systems (FLIR), ICU Medical (ICUI), Progressive (PGR),ProPetro Holding (PUMP), ServiceNow (NOW), SS&C (SSNC), SVB Financial (SIVB), UnitedHealth (UNH), and Weyerhaeuser (WY).
11/15/17
11/15/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tyson Foods (TSN) upgraded to Buy from Hold at Argus with analyst John Staszak saying the company's wide range of food business offerings gives it an edge over less diversified competitors, adding that growing demand for meat products will result in better than expected operating income over the next two years. 2. Sangamo (SGMO) upgraded to Overweight from Neutral at Piper Jaffray with analyst Charles Duncan saying he sees a "reinvigorated" company with a reestablished clinical stage pipeline. 3. Alaska Air (ALK) upgraded to Strong Buy from Outperform at Raymond James with analyst Savanthi Syth saying risk/reward is compelling following the recent pullback. 4. Ingredion (INGR) upgraded to Overweight from Equal Weight at Stephens with analyst Farha Aslam saying she views the company being well positioned to deliver double-digit EPS growth given an improving product mix, recovery in South America, and cash flow that can be deployed for dealmaking or share repurchases. 5. Tesaro (TSRO) upgraded to Outperform from Market Perform at Leerink with analyst Seamus Fernandez citing more favorable risk/reward, particularly for longer term shareholders, and recent weakness in the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ORCL Oracle
$48.30

-1.89 (-3.77%)

12/15/17
ADAM
12/15/17
NO CHANGE
Target $53
ADAM
Buy
Canaccord lowers Oracle price target to $53 after 'not that good' report
Canaccord analyst Richard Davis said Oracle's Q2 report was "not that good" and "confusing, to say the least." However, he said he is willing to give the company one more quarter to prove it has not become a value trap. Davis, who lowered his outlook on cloud revenue, cloud gross margins and overall operating margins following the report, keeps a Buy rating on Oracle but cut his price target on the shares to $53 from $57.
12/15/17
RBCM
12/15/17
DOWNGRADE
Target $51
RBCM
Sector Perform
Oracle downgraded to Sector Perform at RBC Capital on lower cloud revenue view
As reported earlier, RBC Capital analyst Ross MacMillan downgraded Oracle to Sector Perform from Outperform and lowered his price target to $51 from $53 after Q2 results. MacMillan says that while better near-term license sales prospects buffer software revenue, bigger license declines can be expected in Q4 and beyond based on the difficult comps and "maturing 12cR2 cycle". The analyst adds that he struggles to find potential catalysts amid more challenging competitive dynamics.
12/15/17
MSCO
12/15/17
NO CHANGE
Target $50
MSCO
Equal Weight
Oracle 'confounding' Cloud strategy likely caps multiple, says Morgan Stanley
Morgan Stanley analyst Keith Weiss said Oracle's license business is sustaining better than expected due to a more robust on-premise spending environment and the long-awaited 12c database cycle, but he notes that its Cloud revenues and margins missed expectations. The company's Cloud strategy "continues to confound investors," which will likely keep a near-term cap on the stock's multiple, contends Weiss, who raised his price target on Oracle to $50 from $47 but keeps an Equal Weight rating on the name.
12/15/17
12/15/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. RBC Capital analyst Ross MacMillan downgraded Oracle (ORCL) to Sector Perform from Outperform and lowered his price target to $51 from $53 after Q2 results. MacMillan says that while better near-term license sales prospects buffer software revenue, bigger license declines can be expected in Q4 and beyond based on the difficult comps and "maturing 12cR2 cycle". 2. JMP Securities analyst Andrew Boone downgraded Criteo (CRTO) to Market Perform from Outperform and Citi analyst Mark Kelley downgraded Criteo to Neutral, with both citing uncertainty around Apple's (AAPL) potential response to the company's workaround of the tech giant's Intelligent Tracking Prevention. 3. Stifel analyst Jim Duffy downgraded Fitbit (FIT) to Sell from Hold as he expects the company will remain unprofitable and burn cash in 2018. 4. JPMorgan analyst Andrea Teixeira downgraded e.l.f. Beauty (ELF) to Underweight, as she expects continued deterioration in sell-through rates in tracked channels to limit the company's ability to hit its 20%-plus long-term revenue growth target.5. Goldman Sachs analyst Jami Rubin removed Amgen (AMGN) from the Conviction Buy List but maintained a Buy rating on the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
HUM Humana
$253.64

3.03 (1.21%)

12/13/17
COWN
12/13/17
NO CHANGE
Target $285
COWN
Outperform
Cowen calls Humana a best idea for 2018, ups target to $285
Cowen analyst Christine Arnold raised her price target for Humana to $285 from $275 and names the stock a best idea for 2018. The analyst expects Medicare Advantage enrollment growth to accelerate in 2018 and believes a lower corporate tax rate could meaningfully benefit the company's earnings. She keeps an Outperform rating on Humana.
11/10/17
BMOC
11/10/17
NO CHANGE
Target $290
BMOC
Outperform
Humana price target lowered to $290 from $300 at BMO Capital
BMO Capital analyst Matt Borsch lowered his price target on Humana to $290 following Q3 results to account for lower than expected initial FY18 EPS outlook. The analyst attributes some of the caution to increased competition in Medicare, but says the multi-year growth outlook remains strong. Borsch keeps his Outperform rating on Humana, saying the company also remains a possible acquisition target as the only Medicare Advantage pure play.
11/27/17
LEER
11/27/17
NO CHANGE
Target $280
LEER
Outperform
Cigna most likely acquirer of Humana in any potential transaction, says Leerink
Leerink analyst Ana Gupte notes that a Change of Control 8-K filed by Humana (HUM) suggests that the company is a possible take-out target after the Medicare Advantage Annual Enrollment Season, though the company maintains that this is a needed refresh with broader policy guidelines, rather than individually driven. The analyst sees Cigna (CI) as the most likely acquirer in any potential transaction and able to offer as much as 6% accretion in year 2 and 12% in year 3 post close. However, Anthem (ANTM) and even Wal-Mart (WMT) or Walgreens Boots Alliance (WBA) could be other dark horse acquirers, she contends. Gupte expects that Cigna would need to divest its legacy Health Spring MA assets to satisfy anti-trust regulators, with multiple possible buyers for the assets including WellCare (WCG), Aetna (AET) and Anthem. The analyst reiterates an Outperform rating and $280 price target on Humana shares.
12/06/17
COWN
12/06/17
NO CHANGE
COWN
Tax reform best for Medicare Advantage products, says Cowen
Cowen analyst Christine Arnold reviewed the tax reform implications for the managed care sector and believes the lower tax rate will be most beneficial for Medicare Advantage products as it could allow companies to offset a portion of the non-tax deductible headwind, allowing for stronger margins and/or enhanced benefits for seniors. She believes the lower tax rate would be most positive for Molina (MOH) and WellCare (WCG) given their domestic exposure, but it would also lead to a 15% earnings increase above her projections for Aetna (AET), Anthem (ANTM), Centene (CNC) and Humana (HUM).
KND Kindred Healthcare
$8.60

0.45 (5.52%)

11/20/17
STFL
11/20/17
UPGRADE
Target $7
STFL
Hold
Kindred Healthcare upgraded to Hold from Sell at Stifel
Stifel analyst Chad Vanacore upgraded Kindred Healthcare to Hold from Sell, stating that he expects the share price and earnings to remain volatile but much of the downside has been captured. The company's margins should be aided by the exit of its skilled nursing business, but Vanacore thinks additional significant cost savings will be needed to reach management's targets, he tells investors. He maintains a $7 price target on Kindred Healthcare shares.
07/26/17
STFL
07/26/17
NO CHANGE
STFL
CMS proposal negative for home health providers, says Stifel
Stifel analyst Chad Vanacore says that CMS proposed a 0.4% cut reduction in Medicare payments to home health agencies in 2018 and "potential deep cuts" in 2019. He views this development as negative for companies in the sector, "especially Kindred Healthcare (KND)." The analyst identifies Ensign Group (ENSG) and Brookdale Senior Living (BKD) as other affected companies in the sector. He keeps a Sell rating on Kindred, a Hold rating on Ensign ,and a Buy rating on Brookdale.
11/16/17
JPMS
11/16/17
NO CHANGE
JPMS
Neutral
Almost Family acquired for 16% premium, says JPMorgan
JPMorgan analyst Gary Taylor says Almost Family's (AFAM) merger of equals with LHC Group (LHCG) amounts to a takeover at a 16% premium, based on LHC's closing price yesterday. Regarding antitrust, the analyst notes that while the deal would propel the third and fourth largest players in the home-health industry to a number two position behind Kindred Healthcare (KND), the industry is "tremendously fragmented." Further, Taylor believes the merger agreement contains "onerous divestiture language." The analyst has a Neutral rating on Almost Family with a $59 price target.
07/26/17
MZHO
07/26/17
DOWNGRADE
MZHO
Neutral
Amedisys downgraded on 'massive' CMS reimbursement cut plan at Mizuho
As previously reported, Mizuho analyst Sheryl Skolnick downgraded Amedisys (AMED) to Neutral from Buy after the Centers for Medicare & Medicaid Services issued a proposed rule that would update the 2018 Medicare payment rates and the wage index for home health agencies, which she called a "body blow" that represents a significant headwind for the industry. The proposed new system not only would cut industry payments by $950M in 2019, but would also make LUPA reimbursement worse, she told investors. Skolnick lowered her price target for Amedisys to $50 from $65, cut her price target for HealthSouth (HLS) to $45 from $47 and trimmed her price target on Kindred Healthcare (KND) to $8 from $9.

TODAY'S FREE FLY STORIES

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

15:26
01/20/18
01/20
15:26
01/20/18
15:26
Hot Stocks
Opdivo, Yervoy combo demonstrates activity in patients with dMMR, MSI-H mCRC »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

  • 08

    Mar

EXEL

Exelixis

$28.00

0.14 (0.50%)

, RHHBY

Roche

$30.69

0.18 (0.59%)

15:22
01/20/18
01/20
15:22
01/20/18
15:22
Hot Stocks
Exelixis presents updated results from Phase 1b clinical trial in CRC »

Exelixis (EXEL) announced…

EXEL

Exelixis

$28.00

0.14 (0.50%)

RHHBY

Roche

$30.69

0.18 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 01

    Feb

  • 08

    Feb

  • 15

    Feb

  • 23

    Feb

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

15:17
01/20/18
01/20
15:17
01/20/18
15:17
Hot Stocks
Array BioPharma updates results from BEACON Phase 3 trial »

Array BioPharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 30

    Jun

SO

Southern Company

$44.44

-0.46 (-1.02%)

15:13
01/20/18
01/20
15:13
01/20/18
15:13
Hot Stocks
Southern Company accelerates restoration efforts in Puerto Rico »

Southern Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.43

0.19 (0.65%)

15:10
01/20/18
01/20
15:10
01/20/18
15:10
Hot Stocks
Teck Resources announces Elkview incident »

Teck Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TWTR

Twitter

$23.66

-0.38 (-1.58%)

14:03
01/20/18
01/20
14:03
01/20/18
14:03
Hot Stocks
Twitter begins notifying users exposed to Russian propaganda during elections »

Twitter, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

, SPX

S&P 500

13:58
01/20/18
01/20
13:58
01/20/18
13:58
Periodicals
Government shuts down on anniversary of Trump presidency, Reuters reports »

President's Trump…

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

13:48
01/20/18
01/20
13:48
01/20/18
13:48
Periodicals
NY Times stock jumps after Facebook's announcement, Recode reports »

Facebook (FB) CEO Mark…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

13:36
01/20/18
01/20
13:36
01/20/18
13:36
Periodicals
Still time to shop Walmart shares as company makes changes, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

CME

CME Group

$154.28

2.07 (1.36%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Bar Association to hold annual meeting »

Derivatives & Futures…

CME

CME Group

$154.28

2.07 (1.36%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BP

BP

$42.40

-0.5 (-1.17%)

C

Citi

$78.30

0.91 (1.18%)

BAC

Bank of America

$31.72

0.24 (0.76%)

CS

Credit Suisse

$19.06

0.13 (0.69%)

CRL

Charles River

$107.89

1.22 (1.14%)

MS

Morgan Stanley

$57.46

1.62 (2.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 15

    Feb

AMGN

Amgen

$189.28

1.69 (0.90%)

, BAYRY

Bayer

$32.05

0.235 (0.74%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2018 ASCO…

AMGN

Amgen

$189.28

1.69 (0.90%)

BAYRY

Bayer

$32.05

0.235 (0.74%)

BLRX

BioLineRx

$1.09

-0.02 (-1.80%)

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

CELG

Celgene

$102.65

0.93 (0.91%)

DNA

Bought by RHHBY

ESALY

Eisai

$56.88

0.115 (0.20%)

EXEL

Exelixis

$28.00

0.14 (0.50%)

HALO

Halozyme

$17.98

0.13 (0.73%)

INCY

Incyte

$93.16

1.24 (1.35%)

IPSEY

Ipsen

$34.65

0.75 (2.21%)

LXRX

Lexicon

$10.44

0.2 (1.95%)

MGNX

MacroGenics

$19.19

0.3 (1.59%)

MRK

Merck

$61.28

0.15 (0.25%)

NVS

Novartis

$86.94

0.53 (0.61%)

SNY

Sanofi

$44.60

0.09 (0.20%)

ONCY

Oncolytics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 02

    Feb

  • 03

    Feb

  • 05

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 02

    Mar

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 17

    May

  • 28

    May

  • 23

    Oct

WLFC

Willis Lease

$26.66

0.05 (0.19%)

18:59
01/19/18
01/19
18:59
01/19/18
18:59
Hot Stocks
Willis Lease announces $1,000 bonus for employees »

Willis Lease announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary at MUFG »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.